Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 34fludarabine 25fludarabine phosphate 24Tacrolimus 24Mycophenolic Acid 23Whole-Body Irradiation 22Busulfan 15Methotrexate 12Melphalan 12Granulocyte Colony-Stimulating Factor 12Antilymphocyte Serum 12thymoglobulin 11Cyclosporine 11Stem Cell Transplantation 10Filgrastim 10Rituximab 9Thiotepa 7Peripheral Blood Stem Cell Transplantation 7Nivolumab 7Dexamethasone 7trametinib 6Radiotherapy 6Mesna 6Cytarabine 6Prednisone 5Calcium Dobesilate 5Bortezomib 5Azacitidine 5Alemtuzumab 5Voriconazole 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hematologic Neoplasms × tenalisib × Clear all
NCT03711604 2024-05-08

Compassionate Use Study of Tenalisib (RP6530)

Rhizen Pharmaceuticals SA

Phase 1/2 Completed
17 enrolled 9 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡